lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Larimar Therapeutics
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
May 14, 2026
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
May 8, 2026
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
May 2, 2026
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
April 30, 2026
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
April 29, 2026
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
April 29, 2026
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
April 28, 2026